spacer
home > ebr > summer 2003 > spr-ms in functional proteomics
PUBLICATIONS
European Biopharmaceutical Review

SPR-MS in Functional Proteomics

As the advent of proteomics switches the emphasis from genes to proteins, increased scientific attention is being paid to techniques that produce detailed information on human proteins. Much interest has been concentrated on identification and structural characterisation of the proteins in a cell, using techniques such as mass spectrometry (MS). The true value of genomic information however, will only be realised when this data is combined with functional characterisation of the proteins in question, using techniques such as surface plasmon resonance (SPR). It is not often that two analytical techniques can be successfully combined to correlate data, whilst simultaneously increasing the quality and quantity of output - but this is the case with SPR and MS.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Stefan Löfås, Vice President and Chief Scientific Officer at Biacore AB

Dr Stefan Löfås holds a PhD and BSc in Organic Chemistry. He has gained extensive technical and scientific experience in the development and commercialisation of bioanalytical instrumentation at Biacore AB, having worked for the company since 1985. He has been deeply involved in the development of Biacore's sensor chip chemistry and applications. He was recently appointed Chief Scientific Officer with responsibility for technical development projects, external scientific collaborations and technical aspects on IPR portfolio. Prior to this, Dr Löfås was Director of Biacore's biochemistry & chemistry department within R&D.

spacer
Dr Stefan Löfås
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cargo Convoy Departs to China Carrying Medical Supplies Donated by Qatar Airways for Coronavirus Relief

2,500,000 face masks and 500,000 bottles of hand sanitizer have been donated by Qatar Airways
More info >>

White Papers

Clinical Trials in Emerging Markets: Goldmines or Landmines?

Pharm-Olam, LLC

Over the past decade, biopharmaceutical companies have increasingly turned to emerging markets as a way to reduce clinical trial costs and timelines. Areas such as Eastern Europe, India, and Latin America—with their ready population of treatment naïve patients—can be an answer to the intense competition for patients seen in developed markets. Many of the countries within these regions may now be considered as “emerged” countries but yet, conducting trials in these regions does require some special attention and expertise. Before deciding to conduct studies in these areas, companies should have a full appreciation for the ethical, medical, regulatory, legal, and operational hurdles that must be surmounted for success. Here we highlight a number of those issues and offer our recommendations for how sponsor companies can deal with them effectively.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement